Our study demonstrates that disrupting the KLF16/MYC loop with BET inhibitors, such as OTX015 or ABBV-744, in combination with chemotherapeutic agents like DDP or gemcitabine, significantly inhibits tumor growth and enhances the sensitivity of BLCA cells to chemotherapy. Here, MYC is linked to bladder transitional cell carcinoma.